Nossent J C, Bronsveld W, Swaak A J
Department of Rheumatology, Daniel den Hoed Clinic, Rotterdam, The Netherlands.
Ann Rheum Dis. 1989 Oct;48(10):810-6. doi: 10.1136/ard.48.10.810.
A prospective study of 110 patients with systemic lupus erythematosus (SLE) was undertaken to evaluate the reliability of clinical signs of lupus nephritis, which developed in 39 (35%) patients. Those patients with SLE who showed no clinical signs of lupus nephritis had an excellent survival rate (10 year survival 93%) and retained normal renal function (serum creatinine less than 130 mumols/l); clinical lupus nephritis developed mainly in the first three years after diagnosis of SLE and was associated with a decreased survival rate (10 year survival 62%). Increased mortality was found in male patients with lupus nephritis over 25 years of age and in female patients with lupus nephritis under 25 years of age, while renal failure rates did not differ between these groups. Treatment of lupus nephritis with high dose prednisone alone or in combination with immunosuppressants did not result in differences in patient survival or renal function preservation. It was concluded that clinical variables are a reliable guide in the management of patients with SLE, and routine use of renal biopsy in these patients is rejected.
对110例系统性红斑狼疮(SLE)患者进行了一项前瞻性研究,以评估狼疮性肾炎临床体征的可靠性,39例(35%)患者出现了狼疮性肾炎。那些没有狼疮性肾炎临床体征的SLE患者生存率极佳(10年生存率93%)且肾功能保持正常(血清肌酐低于130μmol/L);临床狼疮性肾炎主要在SLE诊断后的头三年出现,且与生存率降低相关(10年生存率62%)。发现25岁以上的狼疮性肾炎男性患者和25岁以下的狼疮性肾炎女性患者死亡率增加,而这些组之间的肾衰竭率没有差异。单独使用高剂量泼尼松或联合免疫抑制剂治疗狼疮性肾炎在患者生存率或肾功能保留方面没有导致差异。得出的结论是,临床变量是SLE患者管理中的可靠指南,并且拒绝在这些患者中常规使用肾活检。